|
JPS5116436B1
(enExample)
|
1971-05-31 |
1976-05-24 |
|
|
|
EP0237289A3
(en)
|
1986-03-14 |
1988-07-27 |
Takeda Chemical Industries, Ltd. |
Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
|
|
JP2859791B2
(ja)
|
1992-01-31 |
1999-02-24 |
吉富製薬株式会社 |
４−ブロモメチルビフェニル化合物の製造法
|
|
US5312958A
(en)
|
1992-01-31 |
1994-05-17 |
Takeda Chemical Industries, Ltd. |
Process for producing 4-bromomethylbiphenyl compounds
|
|
JPH10298156A
(ja)
|
1997-04-28 |
1998-11-10 |
Nippon Nohyaku Co Ltd |
置換ハロメチルフェニルカルバミド酸エステル類の製造方法
|
|
RU2233284C2
(ru)
|
1999-03-24 |
2004-07-27 |
Такеда Кемикал Индастриз, Лтд. |
Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
|
|
TWI225863B
(en)
|
1999-03-24 |
2005-01-01 |
Takeda Chemical Industries Ltd |
Thienopyrimidine compounds, their production and use
|
|
KR20030005205A
(ko)
|
2000-02-29 |
2003-01-17 |
다케다 야쿠힌 고교 가부시키가이샤 |
티에노피리미딘 유도체의 제조 방법
|
|
JP2001316391A
(ja)
|
2000-02-29 |
2001-11-13 |
Takeda Chem Ind Ltd |
チエノピリミジン誘導体の製造法
|
|
GB2361917A
(en)
|
2000-05-04 |
2001-11-07 |
Astrazeneca Ab |
Novel thieno[2,3-d]pyrimidinediones
|
|
JP2002088044A
(ja)
|
2000-09-14 |
2002-03-27 |
Sumitomo Seika Chem Co Ltd |
４’−ブロモメチル−２−シアノビフェニルの製造方法
|
|
CN1261437C
(zh)
|
2001-09-04 |
2006-06-28 |
阿克佐诺贝尔公司 |
具有LH与FSH联合激动活性的甘氨酸－取代的噻吩并[2,3－d]嘧啶
|
|
US7569570B2
(en)
|
2002-01-30 |
2009-08-04 |
Takeda Pharmaceutical Company Limited |
Thienopyrimidines, process for preparing the same and use thereof
|
|
ES2217956B1
(es)
|
2003-01-23 |
2006-04-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
|
|
EP1591446B1
(en)
|
2003-01-29 |
2013-03-06 |
Takeda Pharmaceutical Company Limited |
Thienopyrimidine compounds and use thereof
|
|
US7947691B2
(en)
|
2004-07-21 |
2011-05-24 |
Athersys, Inc. |
Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
|
|
US20090131258A1
(en)
|
2004-10-25 |
2009-05-21 |
Nihon Nohyaku Co |
Herbicide compositions for upland farming and control method
|
|
KR20080041662A
(ko)
|
2005-07-22 |
2008-05-13 |
다케다 야쿠힌 고교 가부시키가이샤 |
조기 배란 예방제
|
|
EP2329823A4
(en)
|
2008-09-03 |
2013-04-03 |
Takeda Pharmaceutical |
PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
|
|
JP2010229098A
(ja)
*
|
2009-03-27 |
2010-10-14 |
Central Glass Co Ltd |
イソインドリン誘導体のａ型の結晶形の製造方法及びイソインドリン誘導体のａ型の結晶形
|
|
TWI508962B
(zh)
|
2009-04-22 |
2015-11-21 |
Du Pont |
氮雜環醯胺之固體形態
|
|
PL2900675T3
(pl)
*
|
2012-09-28 |
2019-08-30 |
Takeda Pharmaceutical Company Limited |
Sposób wytwarzania pochodnej tienopirymidyny
|
|
US9458169B2
(en)
|
2013-11-01 |
2016-10-04 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
CA2978223A1
(en)
|
2015-02-26 |
2016-09-01 |
Takeda Pharmaceutical Company Limited |
Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
|
|
JP2017088564A
(ja)
*
|
2015-11-13 |
2017-05-25 |
株式会社トクヤマ |
ミルタザピンの製造方法
|
|
JP6674027B2
(ja)
*
|
2015-12-25 |
2020-04-01 |
シュアンチュー ファーマ カンパニー，リミティド |
キナゾリン誘導体の結晶及びその調製方法
|
|
TWI726969B
(zh)
*
|
2016-01-11 |
2021-05-11 |
比利時商健生藥品公司 |
用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
|
|
US20170275330A1
(en)
*
|
2016-03-28 |
2017-09-28 |
Warsaw Orthopedic, Inc. |
Polymorphic forms of an oxysterol and methods of making them
|
|
EP3518933B2
(en)
|
2016-09-30 |
2025-02-26 |
Sumitomo Pharma Switzerland GmbH |
Methods of treating uterine fibroids and endometriosis
|
|
CN110248661A
(zh)
|
2016-09-30 |
2019-09-17 |
梦欧文科学有限责任公司 |
前列腺癌的治疗
|
|
US12441738B2
(en)
|
2018-03-14 |
2025-10-14 |
Assia Chemical Industries Ltd. |
Solid state forms of Relugolix
|
|
WO2019178304A1
(en)
*
|
2018-03-14 |
2019-09-19 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of relugolix
|
|
EP3666776A1
(en)
*
|
2018-12-11 |
2020-06-17 |
Sandoz AG |
Hydrate of a gonadotropin-releasing hormone receptor antagonist
|
|
WO2020230094A1
(en)
*
|
2019-05-15 |
2020-11-19 |
Dr. Reddy’S Laboratories Limited |
Amorphous and crystalline forms of relugolix
|
|
WO2021026011A1
(en)
*
|
2019-08-02 |
2021-02-11 |
Johnson Matthey Public Limited Company |
Solid-state forms of relugolix
|
|
CN112390812A
(zh)
*
|
2019-08-14 |
2021-02-23 |
苏州鹏旭医药科技有限公司 |
瑞卢戈利化合物的晶型和无定型固体及其制备方法
|
|
CN112771052B
(zh)
|
2019-08-21 |
2023-04-07 |
深圳仁泰医药科技有限公司 |
促性腺素释放激素拮抗剂的晶型及其制备方法和用途
|
|
JP2022551316A
(ja)
|
2019-10-10 |
2022-12-08 |
ミオバント サイエンシズ ゲーエムベーハー |
Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
|
|
EP4041738A1
(en)
|
2019-10-10 |
2022-08-17 |
Myovant Sciences GmbH |
Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
|
|
CN111423452B
(zh)
*
|
2020-03-26 |
2023-08-22 |
江西青峰药业有限公司 |
瑞卢戈利的中间体及其制备方法和应用
|
|
CN111333633B
(zh)
*
|
2020-04-01 |
2023-10-20 |
江西科睿药业有限公司 |
一种瑞卢戈利的中间体化合物及其制备方法和用途
|
|
BR112022023937A2
(pt)
|
2020-05-29 |
2022-12-27 |
Myovant Sciences Gmbh |
Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
|
|
US11655256B1
(en)
|
2020-11-06 |
2023-05-23 |
Macfarlan Smith Limited |
Processes for making a solid-state form of relugolix
|
|
EP4243829A1
(en)
|
2020-11-11 |
2023-09-20 |
Myovant Sciences GmbH |
Methods of administering relugolix
|
|
CN112552312B
(zh)
|
2020-12-07 |
2022-08-05 |
杭州科巢生物科技有限公司 |
一种瑞卢戈利或其盐的合成方法
|
|
CN113620972A
(zh)
|
2021-02-02 |
2021-11-09 |
奥锐特药业(天津)有限公司 |
瑞卢戈利新晶型及其制备方法
|
|
WO2023042214A1
(en)
|
2021-09-15 |
2023-03-23 |
Cipla Limited |
Solid state forms of relugolix
|
|
CN115947734A
(zh)
|
2021-10-09 |
2023-04-11 |
江苏希迪制药有限公司 |
瑞卢戈利溶剂化物的晶型及其制备方法
|
|
WO2023066941A1
(en)
|
2021-10-18 |
2023-04-27 |
Myovant Sciences Gmbh |
Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
|
|
WO2023119333A1
(en)
|
2021-12-25 |
2023-06-29 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of relugolix and its intermediates
|
|
IN202221021078A
(enExample)
|
2022-04-08 |
2023-10-13 |
|
|
|
CN115417883B
(zh)
|
2022-09-16 |
2024-08-27 |
浙江科聚生物医药有限公司 |
一种瑞卢戈利的晶型及其制备方法
|